RESEARCH TRIANGLE PARK, N.C. , May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S.

~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based on Clinical Results Demonstrating Prevention of Ototoxicity and a

~ U.S. Commercial Team in Place with PEDMARK ® Launch Off to Solid Start Following FDA Approval of PEDMARK ®   in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ RESEARCH TRIANGLE PARK, N.C. , March 30, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc.

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK® from its FDA Approval on

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized,  Non-metastatic Solid Tumors ~ ~ The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Percent or

~ In September 2022 , FDA Approved PEDMARK ® , the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK ® in October 2022 ~ ~ Closed $25

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS™ Program Offers Comprehensive Patient Services, Including Access to Care Coordinators, Financial and Prescription Drug Support ~ RESEARCH

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022 , and $20 Million to be Funded Upon FDA Approval of PEDMARK®   Which Occurred on September 20, 2022   ~ ~ Fennec Has the Potential to Access an

~ PEDMARK ® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc.

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARK TM   ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023  ~ RESEARCH TRIANGLE PARK, N.C. , Aug.